2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05306457
(ClinicalTrials.gov)		May 8, 202221/12/2021CNS10-NPC-GDNF Delivered to the Motor Cortex for ALSHuman Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) Delivered to the Motor Cortex for the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: CNS10-NPC-GDNFCedars-Sinai Medical CenterCalifornia Institute for Regenerative Medicine (CIRM)Recruiting18 YearsN/AAll16Phase 1United States
2NCT02943850
(ClinicalTrials.gov)		April 1, 201720/10/2016CNS10-NPC-GDNF for the Treatment of ALSHuman Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: Stem cell (HPC) implantation;Device: Stereotactic surgical deviceCedars-Sinai Medical CenterCalifornia Institute for Regenerative Medicine (CIRM)Completed18 YearsN/AAll18Phase 1United States